Literature DB >> 22192846

Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine.

So Jung An1, Yeon Kyung Yoon, Sudeep Kothari, Deok Ryun Kim, Jeong Ah Kim, Neha Kothari, Eugene Lee, Tai Hyun Park, Rodney Carbis.   

Abstract

The influence pre-exposure of mice to Vi capsular polysaccharide, purified from Salmonella enterica Serovar Typhi, on the subsequent immune response induced by a Vi-diphtheria toxoid (Vi-DT) conjugate was evaluated. Vi induced low anti Vi IgG titers with the dominant subclass being IgG3. The Vi-DT conjugate induced high titers of anti Vi IgG with the dominant subclass being IgG1 but with considerable quantities of IgG2a, IgG2b and IgG3. Priming of mice with Vi suppressed the response to a subsequent dose of conjugate and the suppression was overcome by a second dose of conjugate. Priming with conjugate prevented suppression of the anti Vi response and subsequent dosing with Vi raised titers back to previous levels but did not boost to new higher levels. The anti DT IgG response to one dose of conjugate was relatively strong and protracted and continued to rise for 12 weeks, compared to the response to one dose of DT which was poor and peaked at two weeks. The prolonged anti DT response was most likely due to the slow release of DT from the conjugate lattice as it degrades within the mouse resulting in a continuous stimulation of the immune response. The presence of increasing amounts of un-conjugated Vi, up to 50%, administered with the conjugate resulted in increasingly higher levels of both anti Vi and anti DT. Larger amounts of un-conjugated Vi inhibited the anti Vi response. These findings have implications for vaccine quality and a limit for un-conjugated polysaccharide should not exceed 50% and from a vaccine program perspective if the results presented here translate to humans then a Vi conjugate, once it becomes available, should replace Vi polysaccharide vaccines.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22192846     DOI: 10.1016/j.vaccine.2011.12.046

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.

Authors:  So Jung An; Puthupparampil V Scaria; Beth Chen; Emma Barnafo; Olga Muratova; Charles Anderson; Lynn Lambert; Myung Hwa Chae; Jae Seung Yang; Patrick E Duffy
Journal:  Vaccine       Date:  2018-04-20       Impact factor: 3.641

2.  Development of a synthetic Vi polysaccharide vaccine for typhoid fever.

Authors:  Yawei Ni; Michael J Springer; Jianhua Guo; Isaac Finger-Baker; James P Wilson; Ronald R Cobb; Debra Turner; Ian Tizard
Journal:  Vaccine       Date:  2017-11-14       Impact factor: 3.641

3.  Rotavirus spike protein ΔVP8* as a novel carrier protein for conjugate vaccine platform with demonstrated antigenic potential for use as bivalent vaccine.

Authors:  Wook-Jin Park; Yeon-Kyung Yoon; Ji-Sun Park; Ruchirkumar Pansuriya; Yeong-Jae Seok; Ravi Ganapathy
Journal:  Sci Rep       Date:  2021-11-11       Impact factor: 4.379

4.  A review of vaccine development and research for industry animals in Korea.

Authors:  Nak-Hyung Lee; Jung-Ah Lee; Seung-Yong Park; Chang-Seon Song; In-Soo Choi; Joong-Bok Lee
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31

Review 5.  Vaccines against invasive Salmonella disease: current status and future directions.

Authors:  Calman A MacLennan; Laura B Martin; Francesca Micoli
Journal:  Hum Vaccin Immunother       Date:  2014-05-07       Impact factor: 3.452

6.  Serum bactericidal assay for the evaluation of typhoid vaccine using a semi-automated colony-counting method.

Authors:  Mi Seon Jang; Sushant Sahastrabuddhe; Cheol-Heui Yun; Seung Hyun Han; Jae Seung Yang
Journal:  Microb Pathog       Date:  2016-05-20       Impact factor: 3.738

7.  Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.

Authors:  Maria Rosario Capeding; Samuel Teshome; Tarun Saluja; Khalid Ali Syed; Deok Ryun Kim; Ju Yeon Park; Jae Seung Yang; Yang Hee Kim; Jiwook Park; Sue-Kyoung Jo; Yun Chon; Sudeep Kothari; Seon-Young Yang; Dong Soo Ham; Ji Hwa Ryu; Hee-Seong Hwang; Ju-Hwan Mun; Julia A Lynch; Jerome H Kim; Hun Kim; Jean-Louis Excler; Sushant Sahastrabuddhe
Journal:  Vaccine       Date:  2018-06-18       Impact factor: 3.641

8.  Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.

Authors:  Maria Rosario Capeding; Edison Alberto; Arijit Sil; Tarun Saluja; Samuel Teshome; Deok Ryun Kim; Ju Yeon Park; Jae Seung Yang; Suchada Chinaworapong; Jiwook Park; Sue-Kyoung Jo; Yun Chon; Seon-Young Yang; Dong Soo Ham; Ji Hwa Ryu; Julia Lynch; Jerome H Kim; Hun Kim; Jean-Louis Excler; T Anh Wartel; Sushant Sahastrabuddhe
Journal:  Vaccine       Date:  2019-10-01       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.